tbuckley/cabot-search huggingface dataset:
Brain-Derived Neurotrophic Factor in Autism Spectrum Disorder—Reply
Authors: Xiao-Yan Qin, Yong Cheng
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Nurselike Cells in Chronic Lymphocytic Leukemia (CLL) Express Both BAFF and APRIL that Protect CLL B Cells from Spontaneous Apoptosis by Paracrine Manner.
Authors: Mitsufumi Nishio, Nobuhiro Tsukada, Junko Ohata, Nathan J. Zvaifler, Thomas J. Kipps
Journal: Blood (2004)
Selective laser melting porous metallic implants with immobilized silver nanoparticles kill and prevent biofilm formation by methicillin-resistant Staphylococcus aureus
Authors: Ingmar A.J. van Hengel, Martijn Riool, Lidy E. Fratila-Apachitei, Janneke Witte-Bouma, Eric Farrell, Amir A. Zadpoor, Sebastian A.J. Zaat, Iulian Apachitei
Journal: Biomaterials (2017)
Abstract P3-13-27: Early detection of secondary lymphedema after cancer treatments
Authors: J-P Belgrado, L Vandermeeren, S Vankerckhove, J-B Valsamis, B Carly, D Hertens, I Jeanjot, B Beier, S Etbaz, C De Coster, F Liebens
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Internal Tandem Duplication and Kinase Domain Mutation of FLT3 in Pediatric Acute Myeloid Leukemia Treated on Japan Cooperative AML 99 Protocol.
Authors: Akira Shimada, Takeshi Taketani, Tomohiko Taki, Ken Tabuchi, Ryoji Hanada, Akio Tawa, Masahiro Tsuchida, Keizo Horibe, Ichiro Tsukimoto, Yasuhide Hayashi
Journal: Blood (2004)
Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy.
Authors: Deok-Hwan Yang, Jae Sook Ahn, Yeo-Kyeoung Kim, Je-Jung Lee, Young Jin Choi, Ho Jin Shin, Joo-Seop Chung, Joon Ho Moon, Yee Soo Chae, Jong Gwang Kim, Sang Kyun Sohn, Hyeoung-Joon Kim
Journal: Blood (2008)
Fast-forming hydrogel with ultralow polymeric content as an artificial vitreous body
Authors: Kaori Hayashi, Fumiki Okamoto, Sujin Hoshi, Takuya Katashima, Denise C. Zujur, Xiang Li, Mitsuhiro Shibayama, Elliot P. Gilbert, Ung-il Chung, Shinsuke Ohba, Tetsuro Oshika, Takamasa Sakai
Journal: Nature Biomedical Engineering (2017)
Metabolism in cardiomyopathy: every substrate matters
Authors: Julia Ritterhoff, Rong Tian
Journal: Cardiovascular Research (2017)

Cardiac metabolism is highly adaptive to changes in fuel availability and the energy demand of the heart. This metabolic flexibility is key for the heart to maintain its output during the development and in response to stress. Alterations in substrate preference have been observed in multiple disease states; a clear understanding of their impact on cardiac function in the long term is critical for the development of metabolic therapies. In addition, the contribution of cellular metabolism to growth, survival, and other signalling pathways through the generation of metabolic intermediates has been increasingly noted, adding another layer of complexity to the impact of metabolism on cardiac function. In a quest to understand the complexity of the cardiac metabolic network, genetic tools have been engaged to manipulate cardiac metabolism in a variety of mouse models. The ability to engineer cardiac metabolism in vivo has provided tremendous insights and brought about conceptual innovations. In this review, we will provide an overview of the cardiac metabolic network and highlight alterations observed during cardiac development and pathological hypertrophy. We will focus on consequences of altered substrate preference on cardiac response to chronic stresses through energy providing and non-energy providing pathways.
Imminent rheumatoid arthritis can be identified in primary care
Authors: Kulveer Mankia, Paul Emery
Journal: Annals of the Rheumatic Diseases (2017)

We thank Vega-Morales et al 1 for their interest in our proposed approach for identifying individuals at risk of rheumatoid arthritis (RA) in a primary care setting.2 ,3 The authors agree that primary care is usually the first point of contact for patients with RA when they initially develop symptoms. For this reason, they agree that general practitioners (GPs) are well placed to be involved in screening strategies to identify individuals at risk of progressing to RA.1

Vega-Morales et al advocate the squeeze test (Gaenslen's compression test) as a screening tool to aid GPs in identifying at-risk individuals for onward referral to …
MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival
Authors: Adam D Cohen, Ping Lu, Sacha Gnjatic, James Hoffman, Erika Ritter, Ping Zhou, Julie Teruya-Feldstein, Jodie Tassello, Nicole Hanson, Denise Frosina, Achim Jungbluth, Guenther Koehne, Hani Hassoun, Suresh Jhanwar, Heather Landau, Stephen Nimer, Raymond L. Comenzo
Journal: Blood (2008)
Abstract P4-12-10: Prognostic relevance of caspase 8 polymorphisms for breast cancer
Authors: P Wimberger, K Jan Dominik, B Agnes, S Kurt, C Rainer, K Rainer, S Winfried, B Hagen
Journal: Cancer Research (2017)

Abstract Background: The minor allele of two caspase 8 polymorphisms, namely CASP8 -652 6N InsDel (rs3834129) and CASP8 Asp302His (rs1045485), were repeatedly associated with reduced breast cancer susceptibility. Contrarily, the presence of the -652 6N Del or the CASP8 302His variant was reported to be an unfavorable prognostic factor in colorectal cancer or neuroblastoma. However, prognostic relevance of these genetic variants for breast cancer is completely unknown and is therefore adressed by the current study. Methods: Genotyping was performed by pyrosequencing. Caspase 8 mRNA expression was quantified by comparative RT-qPCR. Results: We observed an allele-dose dependent association between CASP8 -652 6N InsDel and caspase 8 mRNA expression in breast cancer tissue, with homozygous deletion carriers showing lowest relative caspase 8 expression (p=0.0131). Intriguingly, the presence of the -652 6N Del or the 302His variant was shown to be a negative prognostic factor for breast cancer in terms of an allele-dose dependent influence on overall survival (OS, p=0.0018, p=0.0150, respectively). Moreover, both polymorphisms were independent predictors of OS after adjusting for co-variats (p=0.007, p=0.037, respectively). Prognostic relevance of both polymorphisms was independent from ER or Her2/Neu receptor status and a combined analysis of diplotypes revealed an additive influence on OS (p=0.0002). Conclusion: This is the first report, showing negative and independent prognostic impact of the CASP8 -652 6N Del and the 302His variant for breast cancer. Our data provide rationale to further validate clinical utility of these polymorphisms for breast cancer and to extend this investigation to a broad scope of other malignancies. Citation Format: Wimberger P, Jan Dominik K, Agnes B, Kurt S, Rainer C, Rainer K, Winfried S, Hagen B. Prognostic relevance of caspase 8 polymorphisms for breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-12-10.
Acute Pulmonary Hemorrhage/Hemosiderosis Among Infants—Cleveland, January 1993-November 1994
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors.
Authors: Brian J.P. Huntly, Hirokazu Shigematzu, Kenji Deguchi, Benjamin Lee, Shinichi Mizuno, Nicky Duclos, Rebecca Rowan, Sonia Amaral, David Curley, Ifor R. Williams, Koichi Akashi, Gary Gilliland
Journal: Blood (2004)
Abstract B27: Serum uric acid levels as a prognostic factor in male patients with non-metastatic colorectal cancer
Authors: Shin Rumi, Park Ji Won, Lee Dong Woon, Ryoo Seung-Bum, Jeong Seung-Yong
Journal: Cancer Research (2017)

Abstract Objective: Uric acid may be a marker of oxidative stress, and can be act as an antioxidant or a prooxidant. The role of serum uric acid (SUA) in the prognostic impact of cancer is controversial. This study aimed to evaluate whether the preoperative SUA level is associated with long-term outcomes in patients with colorectal cancer (CRC). Methods: Between 2002 and 2010, 2,183 patients, who underwent curative surgical resection for non-metastatic CRC and had available SUA value, were included for this study. We analyzed the association between the overall survival (OS) and SUA level as quartile according to sex, using log-rank test and Cox proportional hazard regression to identify prognostic factors. Results: Mean SUA level was different between male and female (male [n=1,328]: 5.320 ± 1.363, female [n=855]: 4.065 ± 1.180, p&amp;lt;0.001). In female patients, there was no difference in OS according to SUA level. In male patients, SUA levels in the lowest quartile (&amp;lt; 3.5 mg/dL) was associated with poor overall survival (5-year OS of SUA level &amp;lt; 3.5 mg/dL vs ≥ 3.5 mg/dL: 72.0 % vs 97.1 %, p &amp;lt; 0.001). SUA level was an independently significant prognostic factor (HR 1.714, 95% CI 1.306-2.250, p&amp;lt;0.001). Conclusion: Our results do not support the protective role of SUA in CRC cancer, and rather lower SUA concentrations to be associated with poor long-term outcomes in male CRC patients. Citation Format: Shin Rumi, Park Ji Won, Lee Dong Woon, Ryoo Seung-Bum, Jeong Seung-Yong. Serum uric acid levels as a prognostic factor in male patients with non-metastatic colorectal cancer. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr B27.
Abstract 672: Baseline serum albumin as a prognostic factor in patients with stage I and II colon adenocarcinoma
Authors: Luis F. Onate-Ocana
Journal: Cancer Research (2017)

Abstract Background: Patients with stage I or II colon carcinoma (CC) have a significant risk of recurrence after adequately performed curative resection. Adjuvant chemotherapy has not improved recurrence or survival in such patients. In this study, a prognostic model in patients with stage I or II CC is presented. Methods: Consecutive cases with CC treated at a cancer center in Mexico City from January 2008 to December 2014, with diagnosis of adenocarcinoma by colonoscopy and biopsy were included in this cohort. Patients were treated according to standard guidelines. Follow-up continued until June 2016; the Kaplan-Meier method and the Cox model were used to analyze the association of prognostic factors and overall survival (OS). Results: 1,259 cases of CC were treated; only 496 patients have stage I and II CC and were included in the database: 234 women (47.2%) and 262 males (52.8%) and their mean age was 59.9 years (SD 14.9); 96, 339, 31 and 30 cases were pTNM stages I, IIa, IIb and IIc, respectively. Multivariate analysis of prognostic factors is depicted below. Predicted survival functions using this model, defined 4 risk groups that showed better prognostic value than simple TNM stages I-IIc. Conlusion: BSA is an independent, significant, simple, cheap and widely available prognostic factor in patients with CC. BSA and other clinical factors add significant prognostic information to TNM classification. Feasibly, it can be used to develop multivariate prognostic models with clinical impact defining the use of adjuvant chemotherapy. The use of histopathological and immunohistochemical markers could improve the prognostic information of this model. Multivariate análisis of prognostic factorsBetaSEpHR95% CIMale gender0.3550.1660.0321.4261.031-1.973Hemoglobin-0.0880.0380.020.9160.85-0.986Platelet count-0.0020.0010.0010.9980.996-0.999Neutrophil count0.0820.0280.0041.0851.027-1.147Albumin0.7820.2280.0012.1851.397-3.417Albumin/Globulin-1.6240.4880.0010.1970.076-0.513BMI-0.0420.0220.0510.9580.918-1.0TNM 0/I0.0541TNM IIa0.5540.2550.031.741.056-2.869TNM Iib0.7340.4040.0692.0830.944-4.597TNM IIc0.950.3670.012.5861.26-5.305Chemotherapy-0.7650.2&amp;lt;0.00010.4650.315-0.688R0&amp;lt;0.00011R10.2670.4750.5741.3060.515-3.311R20.9360.3480.0072.5511.29-5.044No Resection1.9360.288&amp;lt;0.00016.9323.944-12.18Platelet/Lymphocute ratio0.0010.0010.081.0011.0-1.002 Citation Format: Luis F. Onate-Ocana. Baseline serum albumin as a prognostic factor in patients with stage I and II colon adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 672. doi:10.1158/1538-7445.AM2017-672
Asymptomatic and symptomatic urethral gonorrhoea in men who have sex with men attending a sexual health service
Authors: J.J. Ong, K. Fethers, B.P. Howden, C.K. Fairley, E.P.F. Chow, D.A. Williamson, I. Petalotis, E. Aung, K. Kanhutu, V. De Petra, M.Y. Chen
Journal: Clinical Microbiology and Infection (2017)
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells
Authors: L Poulain, P Sujobert, F Zylbersztejn, S Barreau, L Stuani, M Lambert, T L Palama, V Chesnais, R Birsen, F Vergez, T Farge, C Chenevier-Gobeaux, M Fraisse, F Bouillaud, C Debeissat, O Herault, C Récher, C Lacombe, M Fontenay, P Mayeux, T T Maciel, J-C Portais, J-E Sarry, J Tamburini, D Bouscary, N Chapuis
Journal: Leukemia (2017)
Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress
Authors: Wei Shi, Therese Vu, Didier Boucher, Anna Biernacka, Jules Nde, Raj K. Pandita, Jasmin Straube, Glen M. Boyle, Fares Al-Ejeh, Purba Nag, Jessie Jeffery, Janelle L. Harris, Amanda L. Bain, Marta Grzelak, Magdalena Skrzypczak, Abhishek Mitra, Norbert Dojer, Nicola Crosetto, Nicole Cloonan, Olivier J. Becherel, John Finnie, Jeffrey R. Skaar, Carl R. Walkley, Tej K. Pandita, Maga Rowicka, Krzysztof Ginalski, Steven W. Lane, Kum Kum Khanna
Journal: Blood (2017)
Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Authors: Madlen Jentzsch, Luba Schuhmann, Marius Bill, Sabine Leiblein, Ulrike Bergmann, Martina Pless, Karoline Schubert, Laura Katharina Schmalbrock, Juliane Grimm, Maria Knyrim, Wolfram Poenisch, Georg-Nikolaus Franke, Vladan Vucinic, Michael Cross, Gerhard Behre, Dietger Niederwieser, Sebastian Schwind
Journal: Blood (2015)
Change in Percentages of Adults With Overweight or Obesity Trying to Lose Weight, 1988-2014
Authors: Kassandra R. Snook, Andrew R. Hansen, Carmen H. Duke, Kathryn C. Finch, Amy A. Hackney, Jian Zhang
Journal: JAMA (2017)

Socially acceptable body weight is increasing.1 If more individuals who are overweight or obese are satisfied with their weight, fewer might be motivated to lose unhealthy weight. This study assessed the trend in the percentage of adults who were overweight or obese and trying to lose weight during 3 periods from 1988 through 2014.

We used data from the National Health and Nutrition Examination Survey (NHANES), an ongoing, stratified, multistage probability sample of the US noninstitutionalized population designed to represent the health and nutritional status of the general population. A strength of NHANES is that the sampling approaches, interviews, and physical examination methods are standardized across surveys and have been published extensively elsewhere.2 NHANES protocol was approved by the National Center for Health Statistics institutional review board, and written informed consent was obtained.2 The current analysis was categorized as exempt by the Georgia Southern University institutional review board.
Abstract ES9-2: ES9-2 Metastatic TNBC: New targets/new strategies
Authors: SL Moulder
Journal: Cancer Research (2017)

Abstract Triple negative breast cancer (TNBC) is a diagnosis of exclusion as these tumors lack ER, PR and HER2. Through advances in molecular profiling, the heterogeneity of TNBC has been revealed as subsets with molecular features targetable with either investigational or existing FDA approved drugs. Basal-like TNBCs (BL1 and BL2) are associated with proliferative gene signatures. BL1 tumors demonstrate at higher rate of pCR to standard chemotherapy compared to other subtypes. The BL2 subset demonstrates gene ontologies involving growth factor signaling such as EGFR and IGF1R. Preclinical models demonstrate that basal-like TNBCs have high sensitivity to cisplatin and relative resistance to PI3K inhibitors in cell culture and xenografts. Germ line aberrations in BRCA1 and BRCA2 lead to a defect in DNA repair in cancers harboring such mutationsand these tumors appear to be more sensitive to therapy inducing DNA breaks, such as those induced by platinum based therapies or PARP inhibition. Approximately 30% of TNBCs display mesenchymal features and carry a high rate of molecular aberrations that activate the PI3K/Akt/mTOR axis with clinical data suggesting that this subgroup may be responsive to therapeutic regimens targeting this pathway. Approximately 10-15% of TNBCs are associated with expression of androgen receptor (AR+ or LAR) and are characterized by the expression of luminal genes and a high rate of PI3K activation/mutation. Response to AR and/or PI3K directed therapy has been demonstrated in preclinical models and AR inhibition has demonstrated response in early phase clinical trials. Lastly, though breast cancer is generally considered a non-immunogenic malignancy, some TNBCs have tumor infiltrating lymphocytes. Novel agents to enrich immune response have been associated with durable responses in a subset of patients with metastatic TNBC. In summary, molecular characterization has identified subsets of TNBC that show promising response to existing or emerging targeted agents. Citation Format: Moulder SL. ES9-2 Metastatic TNBC: New targets/new strategies [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES9-2.
Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment
Authors: Daniela S. Krause, Keertik Fulzele, Andre Catic, Michael Hurley, Sanon Lezeau, Eyal C. Attar, Joy Y. Wu, Herbert Yih-Fuu Lin, Paola Divieti-Pajevic, Robert Hasserjian, Ernestina Schipani, Richard A. Van Etten, David T. Scadden
Journal: Blood (2012)
Molecular Diagnosis of Peripheral T-Cell Lymphoma/NOS From Formalin Fixed Paraffin Embedded Tissues,
Authors: Pier Paolo Piccaluga, Antonio De Leo, Maura Rossi, Maria Antonella Laginestra, maria Rosaria Sapienza, Anna Gazzola, Claudia Mannu, Claudio Agostinelli, Francesco Bacci, Elena Sabattini, Sylvia Hartmann, Martin Leo Hansmann, Stefano A Pileri
Journal: Blood (2011)
Abstract CS1-1: The genomics of metastatic breast cancer: What are we learning?
Authors: N Wagle
Journal: Cancer Research (2017)

Abstract Over the past decade, genomic characterization of tumors from cancer patients obtained through large-scale sequencing projects has shed enormous light on the molecular underpinnings of cancer. These discoveries have, in turn, led to the development of novel therapies and preventive measures that have already revolutionized cancer care. Despite this tremendous progress, our understanding of the genomics of metastatic breast cancer – and in particular cancers that have developed resistance to therapies – remains incomplete. In this presentation, we will discuss recent and ongoing studies that focus on the genomics of metastatic breast cancer, and how the learnings from these studies are influencing precision medicine strategies for patients with advanced breast cancer. We will focus on how genomic and molecular characterization of metastatic tumor samples from patients can shed light on the biology of metastatic breast cancer and can enable the development of strategies to overcome or prevent drug resistance. We will discuss the landscape of mutations in metastatic breast cancer, the potential clinical impact of genomic profiling, and the incorporation of genomic information into clinical care and clinical trials. We will also discuss how partnering directly with patients, in projects such as The Metastatic Breast Cancer Project (mbcproject.org), enables rapid identification of large numbers of patients willing to share tumors, saliva, and medical records to accelerate this research. Citation Format: Wagle N. The genomics of metastatic breast cancer: What are we learning? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr CS1-1.
Conditioning Regimens in Stem Cell Transplantations Facilitate Homing by Increasing Bone Marrow SDF-1 through Induction of SDF-1 Gene Transcription.
Authors: Sonja Zweegman, Jeroen J.W.M. Janssen, Floortje L. Kessler, Adriana M.C. Mus, Jacob van den Born, Peter C. Huijgens, Angelika M. Drager
Journal: Blood (2004)